Cancer
Cancer remains one of the leading causes of mortality worldwide, with metastatic breast cancer alone affecting over 2 million women globally and responsible for approximately 670,000 deaths each year.
In the UK, ovarian cancer sees over 7,000 new cases annually, and multiple myeloma accounts for about 16,000 deaths globally.
AIDS-related Kaposi's sarcoma, although rarer, remains a significant concern for immuno-compromised patients.
There is a substantial need for more effective and safer treatment options.
The Problem
Doxorubicin remains essential but highly toxic – It is a cornerstone chemotherapy drug, yet its severe systemic side effects limit dosing, compromise patient wellbeing and reduce treatment success
Cardiac damage from Doxorubicin leads to expensive follow-up care, hospitalisations, and long-term monitoring.
Although liposomal chemotherapy is well-established, current formulations face major limitations: variable particle size distribution, inconsistent drug release profiles, inadequate microenvironment responsiveness, and dose-limiting cardiotoxicity that restricts clinical use.
Chemotherapy needs a fundamental redesign, not just a marginal improvement.
Our Solution
NanoLipo addresses these challenges by leveraging microfluidic technology to produce liposome-encapsulated Doxorubicin with highly-controlled size and drug-loading efficiency.
This liposomal formulation delivers the drug directly to tumour sites, responding to the acidic tumour environment to release Doxorubicin where it is needed most.
This targeted approach minimises impact on healthy tissues, reduces systemic toxicity, and improves the safety profile compared to traditional chemotherapy.